Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics Licenses Roche’s PCR Technology for miRNA Dx Products

NEW YORK (GenomeWeb News) - Rosetta Genomics said today it has licensed PCR technology from Roche Molecular Diagnostics for use in its microRNA-based diagnostic tests.
 
The company plans to use the PCR technology in its efforts to identify microRNA biomarkers in several different sample types and body fluids.
 
Rosetta Genomics a month ago struck a license agreement with Nanogen for its MGB Probe technology, which it also plans to use in the development of its line of diagnostic tests.
 
Rosetta has said that in 2008 it plans to launch diagnostic tests for squamous and non-squamous lung cancers, for mesothelioma and lung adenocarcinoma, and to identify the origin of tumors.
 
Financial terms of the agreement were not released.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.